1. $901 million net loss
2. No marketable product
3. At losing end compared with Moderna, Pfizer and others
So, if the FDA within the next month or so approves it vaccine trial, it might boost the share price temporarily but in the long term, it has to have a better strategy to compete with the bigger boys.
That means, if I wanna long, it will be more of a speculative trade than investment for the long term.
2. No marketable product
3. At losing end compared with Moderna, Pfizer and others
So, if the FDA within the next month or so approves it vaccine trial, it might boost the share price temporarily but in the long term, it has to have a better strategy to compete with the bigger boys.
That means, if I wanna long, it will be more of a speculative trade than investment for the long term.
Note
it falls through the support . So, it might revisit 7.52 levelNote
it did not, fooling most short sellers only to rebound with a bullish engulfing candle.Note
and once more, even if it breaks out of the bearish trend line, it can still heads south like the chart above. 9.59 becomes an important support now to see if the price can hold ,else it will go lowerNote
9.59 support has proven to be a mighty strong one as it shows us a nice bullish candle , ready to charge higher next week.Note
you can see twice it shoot up and comes back now.......and now resting on support at 9.59 once more....Note
It cannot get past 12 dollars and started to falter again.....
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.